Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously reported and revised the nasopharyngeal epithelium specific protein
CCDC19
and identified it as a potential
tumour suppressor
in nasopharyngeal carcinoma. The purpose of this study was to investigate the involvement of
CCDC19
in the pathogenesis of human non-small cell lung cancers (NSCLC). Down-regulated
CCDC19
expression was observed in NSCLC tissues and cells compared to normal tissues. However, reduced protein expression did not correlate with the status of NSCLC progression. Instead, we observed that patients with lower
CCDC19
expression had a shorter overall survival than did patients with higher
CCDC19
expression. Lentiviral-mediated
CCDC19
overexpression significantly suppressed cell proliferation and cell cycle transition from G1 to S and G2 phases in NSCLC cells. Knocking down
CCDC19
expression significantly restored the ability of cell growth in
CCDC19
overexpressing NSCLC cells. Mechanistically
CCDC19
functions as a potential
tumour suppressor
by stimulating miR-184 suppression of C-Myc thus blocking cell growth mediated by the PI3K/AKT/C-Jun pathway. Our studies are the first to demonstrate that reduced expression of
CCDC19
is an unfavourable factor in NSCLC.
...
PMID:Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers. 2497 36